Implant Therapeutics develops genetically engineered, hypoimmunogenic iPSC-derived mesenchymal stromal cells and islet cells incorporating panCELLa FailSafe and Stealth/iACT safety platforms for use as universal off‑the‑shelf therapeutic cells and ex vivo gene therapy vehicles; public information indicates preclinical development and technology-evaluation partnerships but no disclosed clinical trial results yet.[1][2][3][4][5][7]
Bone Therapeutics (research evaluation agreement for access to Implant iPSC-derived MSCs for orthopedic and inflammatory indications)[1]Pluristyx (strategic manufacturing and distribution alliance for iPSC lines containing panCELLa FailSafe and Implant hypoimmunogenic technologies; later full corporate merger)[3][4][5]panCELLa (parent/technology partnership providing FailSafe and Stealth/iACT platforms)[3][4][6][7]Angios Biotech (evaluation of Implant/panCELLa technologies in allogeneic vascular transplants derived from iPSC)[2][6]
Beyond the preview
Go deeper on Implant Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
Trial phase
Status
Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
Partners
Deal terms
Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
Funding rounds
Investors
Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
Peer companies
Targets
Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
Platforms
Patents
Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
Company news
Sources
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Implant Therapeutics.